Up to 40% of MM cases harbor a point mutation in either KRAS (~20%) or NRAS (~20%) and it has been shown that survival of MM cell lines depends on oncogenic RAS [4,9,10]. The gene discussed is KRAS; the disease is Miyoshi myopathy.